Toxicology – Beryllium

Core concept

Beryllium is a lightweight metal whose toxicity is primarily an occupational inhalational disease.

The two major pulmonary syndromes are:

High-level acute exposure → chemical pneumonitis

Chronic exposure/sensitization → chronic beryllium disease (CBD), a granulomatous interstitial lung disease

The key chronic mechanism is:

Beryllium exposure → beryllium sensitization → activation of beryllium-specific T lymphocytes → noncaseating granulomatous inflammation

CBD can closely mimic sarcoidosis.

Forms and Uses

Beryllium is used in:

• Aerospace
• Nuclear industries
• Electronics
• Missile and defense components
• Tool and die manufacturing
• Beryllium-copper alloys
• Dental laboratories
• Metal machining
• Atomic-energy research
• Specialty ceramics

The principal route of occupational toxicity is inhalation of beryllium-containing dusts and fumes.

Exposure may involve:

• Beryllium metal
• Beryllium oxide
• Beryllium salts
• Beryllium-containing alloys

Skin contamination and embedded particles may also cause sensitization and granulomatous reactions.

Toxicity

The severity of acute toxicity depends on:

• Airborne concentration
• Duration of exposure
• Solubility of the compound

NIOSH IDLH

The current NIOSH Immediately Dangerous to Life or Health (IDLH) concentration for beryllium compounds is:

4 mg/m³.

This should not be confused with acceptable occupational exposure limits, which are much lower.

Current Occupational Exposure Limits

Current OSHA limits are:

• 8-hour TWA PEL: 0.2 μg/m³
• 15-minute STEL: 2.0 μg/m³
• OSHA action level: 0.1 μg/m³ as an 8-hour TWA

These values are far lower than older historical workplace limits because low-level occupational exposure can cause sensitization, CBD, and contribute to lung-cancer risk.

Pathophysiology

Acute Beryllium Disease

High-level inhalational exposure produces direct inflammatory injury to the respiratory tract:

Beryllium inhalation → airway inflammation → tracheobronchitis/bronchiolitis → chemical pneumonitis ± pulmonary edema

Acute beryllium disease is now uncommon in workplaces with modern exposure controls.

Chronic Beryllium Disease

CBD is primarily a cell-mediated immune hypersensitivity disorder.

Beryllium-specific T cells accumulate in the lungs and thoracic lymph nodes, resulting in:

Chronic inflammation → noncaseating granulomas → progressive interstitial lung disease ± fibrosis

Disease may develop years or even decades after exposure has ended.

Beryllium Sensitization

Beryllium sensitization (BeS) means that the immune system has developed a specific cellular response to beryllium.

Patients with BeS may:

• Be completely asymptomatic
• Have normal chest imaging
• Have normal pulmonary function tests

BeS is identified primarily by the beryllium lymphocyte proliferation test (BeLPT).

Sensitization does not automatically mean the patient has chronic beryllium disease.

Clinical Features

Acute Beryllium Toxicity

HEENT / Upper Airway

High-concentration exposure may cause:

• Conjunctivitis
• Nasal irritation
• Epistaxis
• Facial discomfort
• Nasopharyngitis
• Pharyngeal inflammation

Severe historical exposures have caused:

• Ulceration
• Fissuring
• Nasal tissue injury

Pulmonary

Symptoms may include:

• Dry cough
• Chest pain
• Dyspnea
• Wheezing
• Rhonchi
• Tracheobronchitis
• Chemical pneumonitis
• Pulmonary edema
• Hypoxemia

Severe cases can progress to respiratory failure.

Chronic Beryllium Disease

Respiratory

Typical manifestations include:

• Progressive exertional dyspnea
• Chronic dry cough
• Reduced exercise tolerance
• Chest discomfort

Constitutional

Possible findings include:

• Fatigue
• Weight loss
• Fever
• Myalgias

Physical Findings

As disease progresses:

• Bibasilar crackles
• Wheezing
• Cyanosis
• Digital clubbing
• Hilar or mediastinal lymphadenopathy

ATSDR notes that early disease may be subtle or even asymptomatic.

Advanced Disease

Progressive CBD may result in:

• Pulmonary fibrosis
• Chronic hypoxemia
• Pulmonary hypertension
• Cor pulmonale
• Right-sided heart failure
• Respiratory failure

Dermatologic Effects

Beryllium can cause:

• Contact dermatitis
• Skin ulceration
• Impaired wound healing
• Subcutaneous granulomas

Embedded particles may produce persistent noncaseating granulomas at the site of injury and may contribute to sensitization.

Diagnosis

The older diagnostic checklist based on “four of six criteria” has largely been replaced by a more immunologically based approach.

Modern diagnosis emphasizes:

Evidence of beryllium sensitization + evidence of beryllium-related pulmonary disease

Current diagnostic criteria for CBD require evidence of both BeS and disease characterized by pulmonary inflammation/granuloma formation.

Occupational History

A detailed exposure history is essential.

Ask about:

• Aerospace work
• Nuclear facilities
• Electronics
• Metal machining
• Dental laboratories
• Beryllium-copper alloy production
• Defense industries
• Abrasive blasting
• Past employment many years earlier

Even apparently minor exposure can be clinically relevant.

Beryllium Lymphocyte Proliferation Test

The BeLPT is the principal test used to identify beryllium sensitization.

It measures proliferation of the patient’s lymphocytes when exposed to beryllium salts in vitro.

It can be performed using:

• Peripheral blood lymphocytes
• Bronchoalveolar lavage lymphocytes

Abnormal blood BeLPT results are generally confirmed with repeat testing because test variability can occur.

Bronchoscopy

Patients with suspected CBD may undergo:

Bronchoalveolar Lavage

BAL may show:

• Lymphocytic inflammation
• Positive BAL BeLPT

Transbronchial Lung Biopsy

Typical pathology includes:

• Noncaseating granulomas
• Mononuclear interstitial inflammation
• Variable pulmonary fibrosis

These findings closely resemble sarcoidosis.

Imaging

Chest X-ray

May be:

• Normal in early disease
• Diffusely interstitial
• Nodular
• Associated with hilar adenopathy

High-Resolution CT

HRCT is more sensitive than plain radiography and may demonstrate:

• Interstitial abnormalities
• Pulmonary nodules
• Fibrosis
• Hilar or mediastinal lymphadenopathy

A normal radiograph does not exclude early CBD.

Pulmonary Function Tests

Pulmonary function testing may be:

• Normal early
• Obstructive
• Restrictive
• Mixed

A reduction in DLCO may occur as pulmonary involvement progresses.

Exercise testing may reveal abnormalities before severe resting impairment becomes apparent.

Differential Diagnosis

The most important differential diagnosis is:

Sarcoidosis

Other possibilities include:

• Tuberculosis
• Silicosis
• Hypersensitivity pneumonitis
• Asbestosis
• Fungal infection
• Other interstitial lung diseases
• Pulmonary malignancy

Because sarcoidosis and CBD may be nearly indistinguishable clinically and histologically, occupational history and BeLPT testing are crucial.

Treatment

Acute Exposure

1. Remove from Exposure

Immediately move the patient away from the beryllium-containing environment.

2. Airway and Breathing

Provide:

• Supplemental oxygen when hypoxemic
• Bronchodilators for bronchospasm
• Ventilatory support if respiratory failure develops

Significant pneumonitis or hypoxemia warrants hospital management.

3. Skin Exposure

• Remove contaminated clothing
• Wash exposed skin thoroughly
• Irrigate contaminated wounds

Embedded particles may require specialist evaluation and removal.

Antidote

There is no specific antidote for beryllium toxicity.

Treatment is based on:

• Removal from exposure
• Respiratory support
• Management of inflammation
• Long-term monitoring for sensitization and CBD

Chronic Beryllium Disease

Remove Further Exposure

Further beryllium exposure should be minimized or eliminated whenever possible.

This is important even in sensitized individuals without established CBD.

Beryllium Sensitization Alone

Patients with BeS without clinically significant CBD generally do not require corticosteroids.

They require ongoing surveillance for development or progression of pulmonary disease.

Corticosteroids

Systemic corticosteroids are the principal therapy for symptomatic or progressive chronic beryllium disease.

Treatment is generally considered when there is:

• Significant dyspnea
• Severe cough
• Declining pulmonary function
• Deteriorating gas exchange
• Pulmonary hypertension
• Cor pulmonale

Prednisone is commonly used and tapered to the lowest dose that controls disease activity.

Treatment may need to continue for prolonged periods because disease activity can recur when corticosteroids are reduced.

Steroid-Sparing Therapy

In selected patients requiring prolonged treatment, specialist-directed therapies such as:

• Methotrexate
• Azathioprine

may be considered to reduce long-term corticosteroid exposure.

Supportive Treatment

Depending on severity:

• Supplemental oxygen
• Bronchodilators
• Pulmonary rehabilitation
• Influenza vaccination
• Pneumococcal vaccination
• Treatment of respiratory infections
• Management of pulmonary hypertension/right-heart failure

Monitoring

Patients with CBD should be followed with serial:

• Clinical assessment
• Pulmonary function tests
• DLCO
• Oxygenation assessment
• Exercise testing
• Chest imaging when indicated

Patients with isolated beryllium sensitization also require periodic monitoring because some subsequently develop CBD.

Carcinogenicity

Occupational beryllium exposure is associated with lung cancer risk, in addition to sensitization and chronic beryllium disease. OSHA specifically cites CBD and lung cancer among the major health risks addressed by its current exposure standard.

Prognosis

Acute Disease

Acute chemical pneumonitis may improve after exposure ends, although severe injury can produce prolonged respiratory impairment.

Chronic Disease

CBD has a variable course.

Some patients remain stable for long periods, whereas others develop progressive:

• Granulomatous inflammation
• Pulmonary fibrosis
• Hypoxemia
• Pulmonary hypertension
• Cor pulmonale
• Respiratory failure

There is no definitive cure for established CBD, although treatment can improve symptoms and stabilize disease.

Important Pitfalls

1. Misdiagnosing CBD as sarcoidosis

CBD may look almost identical to sarcoidosis clinically, radiologically, and histologically.

Always obtain a detailed occupational history.

2. Assuming a normal chest X-ray excludes disease

Early CBD may have a normal chest radiograph.

3. Confusing sensitization with disease

A positive BeLPT indicates beryllium sensitization, but does not alone establish clinically significant CBD.

4. Using the older diagnostic checklist

Modern diagnosis emphasizes:

BeLPT evidence of sensitization + evidence of pulmonary granulomatous disease

rather than the historical four-of-six diagnostic criteria.

5. Ignoring apparently minor exposure

Even relatively low or remote exposure may be important.

6. Missing skin exposure

Embedded particles can cause:

• Granulomas
• Ulceration
• Poor wound healing
• Sensitization

7. Using outdated workplace limits

Current OSHA limits are:

0.2 μg/m³ over 8 hours

and

2.0 μg/m³ over 15 minutes.

High-Yield Toxicology Pearls

Beryllium = occupational exposure + granulomatous lung disease

Think:

Beryllium exposure + progressive dyspnea + noncaseating granulomas → consider chronic beryllium disease

Key points:

• Main route: inhalation
• Acute high-level exposure → chemical pneumonitis
• Chronic toxicity is primarily immune-mediated
• Main target organs: lungs and thoracic lymph nodes
• Beryllium sensitization is detected by BeLPT
• CBD requires evidence of sensitization plus pulmonary disease
• Histology shows noncaseating granulomas
• CBD strongly resembles sarcoidosis
• Chest X-ray may be normal early
• PFTs may show obstructive, restrictive, or mixed disease
• DLCO may be reduced
• No specific antidote
• Symptomatic/progressive CBD is treated primarily with systemic corticosteroids
• Sensitization without active disease generally requires surveillance rather than steroids
• Current OSHA TWA PEL: 0.2 μg/m³
• Current OSHA STEL: 2.0 μg/m³
• NIOSH IDLH: 4 mg/m³
• Beryllium exposure is also associated with lung cancer risk